uploads///Geographic Segment

Locating Mylan’s Geographic Market Strategy


Jan. 5 2016, Updated 2:50 p.m. ET

Mylan’s geographic market strategy

Mylan NV’s (MYL) key markets are distributed across the following three segments:

  1. North America
  2. Europe
  3. Rest of the World

The company’s key customers include distributors, wholesalers, retail pharmacy chains, long-term care facilities, and mail order pharmacies.

Article continues below advertisement

Mylan’s North American theater

Mylan’s North American market is made up of US market and Canadian market. Compared to peers Teva Pharmaceuticals (TEVA), Valeant Pharmaceuticals International (VRX), and Zoetis (ZTS), Mylan earns substantially high revenues from the US generic market. The company offers oral solid dosages, injectable, transdermal products, and unit doses. In Canada, Mylan has a product portfolio comprised of approximately 170 products.

Mylan’s European front

In Europe, Mylan is operating in 22 countries including Germany, the UK, France, Italy, Spain, Poland, and Portugal. In terms of market share, Mylan holds the number one position in France, the number two position in Italy, and the number three position in Portugal. The company also has penetrated deeply in the generic drug markets of Germany, the Netherlands, the UK, and Poland.

Article continues below advertisement

Mylan sees action in the rest of the world

Mylan generates revenue from the rest of the world markets through its subsidiaries, present in India, Australia, Japan, New Zealand, Brazil, and Taiwan. The FDA (US Food and Drug Administration) has approved eight APIs (active pharmaceutical ingredient) facilities, two FDFs (finished dosage firm) facilities, and four injectable facilities in India—initiatives that have made Mylan India one of the largest API manufacturers in the world.

A recent acquisition

Mylan has recently acquired Famy Care, a leader in the female hormonal contraceptive segment, in order to increase its presence in women’s healthcare space. Mylan also supplies HIV (human immunodeficiency virus) medicine to the NACO (Indian National AIDS Control Organization).

You can get diversified exposure to Mylan’s stock by investing in the iShares US Pharmaceuticals ETF (IHE), which has 3.6% of its total holdings in Mylan.

Now let’s take a look at Mylan’s segments.


More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.